中礦資源(002738.SZ):所屬春鵬鋰業年產3.5萬噸高純鋰鹽建設項目目前進展順利,預計2023年底前投產
格隆匯6月20日丨有投資者於投資者互動平台向中礦資源(002738.SZ)提問,“請問公司‘津巴布韋Bikita鋰礦200萬t/a改擴建工程”和“津巴布韋Bikita鋰礦200萬t/a建設工程’是否已經建成投產?預計達產日期是什麼時候?春鵬鋰業年產3.5萬噸高純鋰鹽項目目前進度是否符合計劃,在9月份建成?預計達產日期會在什麼時候?”
公司回覆稱,公司Bikita礦山新建200萬噸/年選礦建設工程和200萬噸/年選礦改擴建工程,計劃於2023年陸續建成投產。公司所屬春鵬鋰業年產3.5萬噸高純鋰鹽建設項目目前進展順利,預計2023年底前投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.